

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10001245
Filing Date	2001-11-15
First Named Inventor	Holm et al.
Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	27554-0007001

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO199733910			1997-09-18	KING, TE		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10001245
		Filing Date	2001-11-15
		First Named Inventor	Holm et al.
		Art Unit	1644
		Examiner Name	Nora Maureen Rooney
		Attorney Docket Number	27554-0007001

	1	Letter on behalf of patentee ALK Abello A/S dated August 27, 2010, filed in connection with opposition to EP application 99907345.5 (EP 1 062 341), 5 pages	<input type="checkbox"/>
	2	Preliminary opinion of the Opposition Division dated September 22, 2010, in connection with opposition to EP application 99907345.5 (EP 1 062 341), 7 pages	<input type="checkbox"/>
	3	Letter of opponent Merck Patent GmbH dated February 10, 2011, filed in connection with opposition to EP application 99907345.5 (EP 1 062 341), 2 pages	<input type="checkbox"/>
	4	Abstracts 060, 061, 063, 064 und 240, EAACI Rhodos 1997; Eur. J. Allergy Clin. Immunol. No. 37, Vol 52, 1997	<input type="checkbox"/>
	5	BREITENEDER, H. et al., Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties, Eur. J. Biochem., Vol. 212, pages 355-362, 1993	<input type="checkbox"/>
	6	FERREIRA, F. et al., Dissection of Immunoglobulin E and T Lymphocyte Reactivity of Isoforms of the Major Birch Pollen Allergen Bet v 1: Potential Use of Hypoallergenic Isoforms for Immunotherapy, J. Exp. Med., Vol. 183, 599-609, 1996	<input type="checkbox"/>
	7	LEBECQUE, S. et al., Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1, J. Allergy Clin. Immunol., Vol. 99, No. 3, pages 374-384, 1997	<input type="checkbox"/>
	8	KIM J.-J. P. and J. Wu, Structure of the medium-chain acyl-CoA dehydrogenase from pig liver mitochondria at 3-A resolution, Proc. Natl. Acad. Sci., Vol. 85, pages 6677-6681, 1988	<input type="checkbox"/>
	9	Abbildungen Figs. 1, 2, 3, 4a und 4b, und Fig. 5, raumliche Abbildungen und Sequenzalignments erstellt von Herrn Dr. Andreas Nandy anhand öffentlich zugänglicher Sequenz- und Raumstruktur-Datenbanken	<input type="checkbox"/>
	10	JOST, K. et al., Spezifische Immuntherapie mit dem hypoallergenen, rekombinanten Birkenpollen-Derivat rBet v I-FV: Ergebnisse einer Phase-III-Studie, Poster, 2. Gemeinsamer Deutscher Allergie Kongress Lübeck 2007	<input type="checkbox"/>
	11	JOST, K. et al., Spezifische Immuntherapie mit dem hypoallergenen, rekombinanten Birkenpollen-Derivat rBet v I-FV: Ergebnisse nach 2 Jahren einer Phase-II-Studie, Poster, ADA Lübeck 2007	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10001245
		Filing Date	2001-11-15
		First Named Inventor	Holm et al.
		Art Unit	1644
		Examiner Name	Nora Maureen Rooney
		Attorney Docket Number	27554-0007001

	12	KETTNER, J. et al., Specific immunotherapy with recombinant birch pollen allergen rBet v I-FV results of 2 years of treatment (Phase II trial), Poster, EAACI Goteborg 2007	<input type="checkbox"/>
	13	AKDIS, C. A. et al., Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants, Eur. J. Immunol., Vol. 28, pages 914-925, 1998	<input type="checkbox"/>
	14	MULLER, U. et al, Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom, J. Allergy Clin. Immunol. Vol. 101, No. 6, pages 747-754, 1998	<input type="checkbox"/>
	15	Minutes of Oral Proceedings held on April 11, 2011, in connection with opposition to EP application 99907345.5 (EP 1 062 341), 10 pages	<input type="checkbox"/>
	16	Decision revoking the European patent, dated June 10, 2011 in connection with opposition to EP application 99907345.5 (EP 1 062 341), 17 pages	<input type="checkbox"/>
	17	Ground of Appeal on behalf of patentee ALK Abello A/S October 20, 2011, filed in connection with opposition to EP application 99907345.5 (EP 1 062 341), 67 pages	<input type="checkbox"/>
	18	Preliminary opinion of the Opposition Division dated December 12, 2010, in connection with opposition to EP application 01996610.0 (EP 1 373 510), 11 pages	<input type="checkbox"/>
	19	Letter on behalf of patentee ALK-Abello A/S dated January 17, 2011, filed in connection with opposition to EP application 01996610.0 (EP 1 373 510), 2 pages	<input type="checkbox"/>
	20	Letter of opponent Merck Patent GmbH dated July 18, 2011, filed in connection with opposition to EP application 01996610.0 (EP 1 373 510), 2 pages	<input type="checkbox"/>
	21	BREITENEDER, H. et al., Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties, Eur. J. Biochem., Vol. 212, pages 355-362, 1993	<input type="checkbox"/>
	22	Letter and Auxiliary Requests on behalf of patentee ALK-Abello A/S dated July 20, 2011, filed in connection with opposition to EP application 01996610.0 (EP 1 373 510), 73 pages	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10001245
	Filing Date		2001-11-15
	First Named Inventor		Holm et al.
	Art Unit		1644
	Examiner Name		Nora Maureen Rooney
	Attorney Docket Number		27554-0007001

23	HOLM., J. et al., Allergy Vaccine Engineering: Epitope Modulation of Recombinant Bet v 1 Reduces IgE Binding but Retains Protein Folding Pattern for Induction of Protective Blocking-Antibody Responses ¹ , The Journal of Immunology, pages 5258 - 5267, 1994	<input type="checkbox"/>
24	Minutes of Oral Proceedings held on September 20, 2011, in connection with opposition to EP application 01996610.0 (EP 1 373 510), 32 pages	<input type="checkbox"/>
25	Interlocutory decision of Opposition Division dated November 4, 2011, in connection with opposition to EP application 01996610.0 (EP 1 373 510), 198 pages	<input type="checkbox"/>
26	LARSEN et al., Cross reactive B-cell epitopes on the Betulaceae pollen major allergens identified by 3-D structural analysis an in vitro site directed mutagenesis of Be v 1, J Allergy Clin Immunol, Program and Abstracts of papers to be presented during scientific sessions AAAAI 54th Annual Meeting, March 13-18, 1998, 101(1) Part 2, page S229 Abstract 951	<input type="checkbox"/>
27	SPANGFORT et al., IgE Binding Epitopes of Birch Pollen Bet v 1 revealed by X-ray crystallography and site-directed mutagenesis, J Allergy Clin Immunol, Program and Abstracts of papers to be presented during scientific sessions AAAAI 55th Annual Meeting, February 26-March 3, 1999, 103(1) Part 2, page 122 Abstract 469	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10001245
	Filing Date		2001-11-15
	First Named Inventor		Holm et al.
	Art Unit		1644
	Examiner Name		Nora Maureen Rooney
	Attorney Docket Number		27554-0007001

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.
 The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mitchell Bernstein, Reg. No. 46,550/	Date (YYYY-MM-DD)	2011-11-07
Name/Print	Mitchell Bernstein	Registration Number	46,550

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.